SlideShare a Scribd company logo
1 of 2
Download to read offline
ApplicationNote

Unlock miRNA expression profiles from FFPE samples
using miScript® miRNA PCR Arrays
Krishna Amin and Jonathan M. Shaffer, Ph.D.

1.E+04

miRNA expression profiling provides a valuable window into changes
occurring in a biological system. Due to their stability and size, miRNAs can
be readily extracted from FFPE samples using the miRNeasy FFPE Kit. Here,
we use the miScript PCR System to profile miRNA expression changes in
total RNA samples isolated from FFPE normal and tumor lung tissues.

Profile miRNA expression data in FFPE tissue

from tissues. miScript miRNA PCR Arrays have been organized into
biological and disease-focused panels using state-of-the-art bioinformatics

1.E+04

reverse crosslinking and efficiently release total RNA containing miRNA

1.E-04
1.E+03

transcription reactions. The miRNeasy FFPE Kit is specifically optimized to

1.E-03
1.E+02

can be heavily fragmented, and formalin crosslinking can impair reverse

1.E-02

1.E+01

material for cDNA synthesis (Table 1). RNA isolated from FFPE samples

1.E-01

1.E+00

miRNA PCR Arrays, and uses total RNA that contains miRNA as the starting

1.E+00

1.E-01

RT Kit, miScript SYBR® Green PCR Kit, miScript Primer Assays, and miScript

1.E+01

1.E-02

archived FFPE samples. The miScript PCR System consists of the miScript II

1.E+02

1.E-03

provides a sample-to-result solution for miRNA expression profiling using

1.E+03

1.E-04

The miScript PCR System, in conjunction with the miRNeasy FFPE Kit,

2-∆CT : Tumor lung FFPE tissue

QIAGEN Inc., Frederick, MD, USA

2-∆CT : Normal lung FFPE tissue

Figure 1. miRNA expression changes identified in
tumor lung tissue. A scatter plot of 2-∆CT values shows
significant differences in mature miRNA expression levels
between normal and tumor lung tissue. These include miRNAs
whose expression levels have been previously shown to be
up-regulated (hsa-miR-9, hsa-miR-18a, hsa-miR-210) and
down-regulated (hsa-miR-126, hsa-miR-143) in lung cancer
(1-4). For this experiment, 5 µm FFPE lung tissue sections were
purchased from Asterand, and total RNA was prepared using
the miRNeasy FFPE Kit. 125 ng RNA was reverse transcribed
using the miScript II RT Kit with miScript HiSpec Buffer, and
0.5 ng cDNA was added to each well of the Human miFinder
miScript miRNA PCR Array.

algorithms and text mining tools. These panels profile the most relevant

Pathways for miScript miRNA PCR Arrays

miRNA expression changes in total RNA from FFPE samples (Figure 1), with

„„ Complete miRNome

highly reproducible, reliable results (Figure 2).
Table 1. FFPE tissue recommendations
Step

Starting materials/conditions

Formalin
fixation/paraffin
embedding

Use tissue less than 5 mm thick. Fix in 4–10% neutral-buffered
formalin with a maximum fixation time of 24 hours.

Total RNA
preparation from
FFPE tissues

Use sections 5–20 mm thick, or multiple sections with combined
thickness no greater than 40 mm and surface area <250 mm2.

RNA input for
cDNA conversion

Use 125 to 250 ng per sample for pathway-focused arrays and 250
to 500 ng for whole miRNome.

Amount of FFPE tissue required depends on amount of tissue
embedded and RNA quality. RNA quality will vary due to fixation
and storage conditions.

„„ miFinder
„„ Inflammatory Response & Autoimmunity
„„ Ovarian Cancer
„„ Neurological Development & Disease
„„ Cell Differentiation & Development
„„ Serum & Plasma
„„ Brain Cancer
„„ Breast Cancer
„„ Cancer PathwayFinder
„„ Immunopathology

Sample & Assay Technologies
40

40

Normal

A

32

28

28
CT value

36

32

CT value

36

Tumor

B

24
20
16

24
20
16

FFPE isolation 1
FFPE isolation 2
FFPE isolation 3

12
8

FFPE isolation 1
FFPE isolation 2
FFPE isolation 3

12
8

4

4
1

7 13 19 25 31 37 43 49 55 61 67 73

1

Human miFinder miRNA Assay

7 13 19 25 31 37 43 49 55 61 67 73
Human miFinder miRNA Assay

Figure 2. miScript FFPE
Kit and miFinder miScript
miRNA PCR Array provide
highly reproducible results,
isolation to isolation. The
raw data presented for
one normal A and one
tumor B FFPE lung tissue
donor source demonstrates
the high reproducibility
that can be achieved
using the miRNeasy FFPE
Kit in combination with
the miScript PCR System
and miScript miRNA PCR
Arrays. Each isolation was
from a different section
from the same donor,
with the normal and
tumor tissues coming from
different donors.

Ordering Information
Product

Contents

Cat. no.

miRNome miScript miRNA PCR Array

miRNome panels of miRNA assays

Varies

miScript miRNA PCR Array

Pathway- or disease-focused panels of miRNA assays

Varies

Custom miScript miRNA PCR Array

Custom panels of miRNA assays

Varies

miRNeasy FFPE Kit (50)

Columns, plasticware, and reagents for 50 preps

217504

miScript SYBR® Green PCR Kit (200)

Reagents for 200 x 50 µl PCRs

218073

miScript Primer Assay (100)

miRNA-specific primer for 100 x 50 µl PCRs

Varies*

miScript II RT Kit (12)

Reagents for 12 x 20 µl cDNA synthesis reactions

218160

* Visit GeneGlobe to browse and order these products (www.qiagen.com/GeneGlobe).

Discover more, visit www.qiagen.com/miRNA !
For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual.
QIAGEN kit handbooks and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical
Services or your local distributor.

References
1.	 Liu, C.G., et al. (2004) An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc. Natl. Acad. Sci. USA 101, 9740.
2.	 Crawford, M., et al. (2009) MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem. Biophys. Res. Commun. 388, 483.
3.	 Hayashita, Y., et al. (2005) A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res.
65, 9628.
4.	 Yanaihara, N., et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9, 189.
Trademarks: QIAGEN®, miScript® (QIAGEN Group); SYBR® (Life Technologies Corporation).
1070749 12/2011 © 2011, QIAGEN, all rights reserved.

www.qiagen.com
Australia n 1-800-243-066
Austria n 00800-22448000
Belgium n 00800-22448000
Brazil n 0800-557779

Canada n 0800-362-7737
China n 0800-988-0325
Denmark n 00800-22448000
Finland n 00800-22448000
France n 00800-22448000
Germany n 00800-22448000

Ireland n 00800-22448000
Italy n 00800-22448000
Japan n 03-5632-9610
Luxembourg n 00800-22448000
Mexico n 01-800-7742-436
Netherlands n 00800-22448000

Norway n 00800-22448000
Singapore n 1800-742-4368
Sweden n 00800-22448000
Switzerland n 00800-22448000
UK n 00800-22448000
USA n 1-888-503-3187

Sample & Assay Technologies

More Related Content

What's hot

microRNA Message to T Cell Acute Lymphoblastic Leukemia
microRNA Message to T Cell Acute Lymphoblastic Leukemia microRNA Message to T Cell Acute Lymphoblastic Leukemia
microRNA Message to T Cell Acute Lymphoblastic Leukemia Parisa Naji
 
the role of miRNA in cancer
the role of miRNA in cancerthe role of miRNA in cancer
the role of miRNA in cancermohsen koolivand
 
Defining the relevant genome in solid tumors
Defining the relevant genome in solid tumorsDefining the relevant genome in solid tumors
Defining the relevant genome in solid tumorsThermo Fisher Scientific
 
mRNA-based Therapeutics - Creative Biolabs
mRNA-based Therapeutics - Creative BiolabsmRNA-based Therapeutics - Creative Biolabs
mRNA-based Therapeutics - Creative BiolabsCreative-Biolabs
 
Van criekinge next_generation_epigenetic_profling_vlille
Van criekinge next_generation_epigenetic_profling_vlilleVan criekinge next_generation_epigenetic_profling_vlille
Van criekinge next_generation_epigenetic_profling_vlilleProf. Wim Van Criekinge
 
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131Thermo Fisher Scientific
 
Development of a high throughput workflow for genotyping CFTR mutations
Development of a high throughput workflow for genotyping CFTR mutationsDevelopment of a high throughput workflow for genotyping CFTR mutations
Development of a high throughput workflow for genotyping CFTR mutationsThermo Fisher Scientific
 
2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb
2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb
2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vwebProf. Wim Van Criekinge
 
In Silico Prescription of Anticancer Drugs Reveals Targeting Opportunities
In Silico Prescription of Anticancer Drugs Reveals Targeting OpportunitiesIn Silico Prescription of Anticancer Drugs Reveals Targeting Opportunities
In Silico Prescription of Anticancer Drugs Reveals Targeting OpportunitiesNuria Lopez-Bigas
 
Tumor Mutational Load assessment of FFPE samples using an NGS based assay
Tumor Mutational Load assessment of FFPE samples using an NGS based assayTumor Mutational Load assessment of FFPE samples using an NGS based assay
Tumor Mutational Load assessment of FFPE samples using an NGS based assayThermo Fisher Scientific
 
microRNA discovery and biomarker development in clinical samples
microRNA discovery and biomarker development in clinical samplesmicroRNA discovery and biomarker development in clinical samples
microRNA discovery and biomarker development in clinical samplesexiqon
 
Lopez-Bigas talk at the EBI/EMBL Cancer Genomics Workshop
Lopez-Bigas talk at the EBI/EMBL Cancer Genomics WorkshopLopez-Bigas talk at the EBI/EMBL Cancer Genomics Workshop
Lopez-Bigas talk at the EBI/EMBL Cancer Genomics WorkshopNuria Lopez-Bigas
 
Gene expression profile of the tumor microenvironment from 40 NSCLC FFPE and ...
Gene expression profile of the tumor microenvironment from 40 NSCLC FFPE and ...Gene expression profile of the tumor microenvironment from 40 NSCLC FFPE and ...
Gene expression profile of the tumor microenvironment from 40 NSCLC FFPE and ...Thermo Fisher Scientific
 
Sequencing the circulating and infiltrating T-cell repertoire on the Ion S5TM
Sequencing the circulating and infiltrating T-cell repertoire on the Ion S5TMSequencing the circulating and infiltrating T-cell repertoire on the Ion S5TM
Sequencing the circulating and infiltrating T-cell repertoire on the Ion S5TMThermo Fisher Scientific
 
Lung adenocarcinoma -molecular pathology
Lung adenocarcinoma -molecular pathologyLung adenocarcinoma -molecular pathology
Lung adenocarcinoma -molecular pathologymlahori
 
Micro rna edsc350_macabali
Micro rna edsc350_macabaliMicro rna edsc350_macabali
Micro rna edsc350_macabaliKari Ann Bitgue
 
Insights into the tumor microenvironment and therapeutic T cell manufacture r...
Insights into the tumor microenvironment and therapeutic T cell manufacture r...Insights into the tumor microenvironment and therapeutic T cell manufacture r...
Insights into the tumor microenvironment and therapeutic T cell manufacture r...Thermo Fisher Scientific
 
Widespread human T cell receptor beta variable gene polymorphism: implication...
Widespread human T cell receptor beta variable gene polymorphism: implication...Widespread human T cell receptor beta variable gene polymorphism: implication...
Widespread human T cell receptor beta variable gene polymorphism: implication...Thermo Fisher Scientific
 
Identification of cancer drivers across tumor types
Identification of cancer drivers across tumor typesIdentification of cancer drivers across tumor types
Identification of cancer drivers across tumor typesNuria Lopez-Bigas
 

What's hot (20)

microRNA Message to T Cell Acute Lymphoblastic Leukemia
microRNA Message to T Cell Acute Lymphoblastic Leukemia microRNA Message to T Cell Acute Lymphoblastic Leukemia
microRNA Message to T Cell Acute Lymphoblastic Leukemia
 
the role of miRNA in cancer
the role of miRNA in cancerthe role of miRNA in cancer
the role of miRNA in cancer
 
Defining the relevant genome in solid tumors
Defining the relevant genome in solid tumorsDefining the relevant genome in solid tumors
Defining the relevant genome in solid tumors
 
mRNA-based Therapeutics - Creative Biolabs
mRNA-based Therapeutics - Creative BiolabsmRNA-based Therapeutics - Creative Biolabs
mRNA-based Therapeutics - Creative Biolabs
 
Van criekinge next_generation_epigenetic_profling_vlille
Van criekinge next_generation_epigenetic_profling_vlilleVan criekinge next_generation_epigenetic_profling_vlille
Van criekinge next_generation_epigenetic_profling_vlille
 
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
 
Development of a high throughput workflow for genotyping CFTR mutations
Development of a high throughput workflow for genotyping CFTR mutationsDevelopment of a high throughput workflow for genotyping CFTR mutations
Development of a high throughput workflow for genotyping CFTR mutations
 
2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb
2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb
2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb
 
In Silico Prescription of Anticancer Drugs Reveals Targeting Opportunities
In Silico Prescription of Anticancer Drugs Reveals Targeting OpportunitiesIn Silico Prescription of Anticancer Drugs Reveals Targeting Opportunities
In Silico Prescription of Anticancer Drugs Reveals Targeting Opportunities
 
Role of micro rna in oncogenesis
Role of micro rna in oncogenesisRole of micro rna in oncogenesis
Role of micro rna in oncogenesis
 
Tumor Mutational Load assessment of FFPE samples using an NGS based assay
Tumor Mutational Load assessment of FFPE samples using an NGS based assayTumor Mutational Load assessment of FFPE samples using an NGS based assay
Tumor Mutational Load assessment of FFPE samples using an NGS based assay
 
microRNA discovery and biomarker development in clinical samples
microRNA discovery and biomarker development in clinical samplesmicroRNA discovery and biomarker development in clinical samples
microRNA discovery and biomarker development in clinical samples
 
Lopez-Bigas talk at the EBI/EMBL Cancer Genomics Workshop
Lopez-Bigas talk at the EBI/EMBL Cancer Genomics WorkshopLopez-Bigas talk at the EBI/EMBL Cancer Genomics Workshop
Lopez-Bigas talk at the EBI/EMBL Cancer Genomics Workshop
 
Gene expression profile of the tumor microenvironment from 40 NSCLC FFPE and ...
Gene expression profile of the tumor microenvironment from 40 NSCLC FFPE and ...Gene expression profile of the tumor microenvironment from 40 NSCLC FFPE and ...
Gene expression profile of the tumor microenvironment from 40 NSCLC FFPE and ...
 
Sequencing the circulating and infiltrating T-cell repertoire on the Ion S5TM
Sequencing the circulating and infiltrating T-cell repertoire on the Ion S5TMSequencing the circulating and infiltrating T-cell repertoire on the Ion S5TM
Sequencing the circulating and infiltrating T-cell repertoire on the Ion S5TM
 
Lung adenocarcinoma -molecular pathology
Lung adenocarcinoma -molecular pathologyLung adenocarcinoma -molecular pathology
Lung adenocarcinoma -molecular pathology
 
Micro rna edsc350_macabali
Micro rna edsc350_macabaliMicro rna edsc350_macabali
Micro rna edsc350_macabali
 
Insights into the tumor microenvironment and therapeutic T cell manufacture r...
Insights into the tumor microenvironment and therapeutic T cell manufacture r...Insights into the tumor microenvironment and therapeutic T cell manufacture r...
Insights into the tumor microenvironment and therapeutic T cell manufacture r...
 
Widespread human T cell receptor beta variable gene polymorphism: implication...
Widespread human T cell receptor beta variable gene polymorphism: implication...Widespread human T cell receptor beta variable gene polymorphism: implication...
Widespread human T cell receptor beta variable gene polymorphism: implication...
 
Identification of cancer drivers across tumor types
Identification of cancer drivers across tumor typesIdentification of cancer drivers across tumor types
Identification of cancer drivers across tumor types
 

Similar to An gef mi_scriptffpe

miScript Single Cell Poster
miScript Single Cell PostermiScript Single Cell Poster
miScript Single Cell PosterQIAGEN
 
FFPE Applications Solutions brochure
FFPE Applications Solutions brochureFFPE Applications Solutions brochure
FFPE Applications Solutions brochureAffymetrix
 
Bro gef mi_rna_0212_lr
Bro gef mi_rna_0212_lrBro gef mi_rna_0212_lr
Bro gef mi_rna_0212_lrElsa von Licy
 
Mi rna functional analysis 2013
Mi rna functional analysis 2013Mi rna functional analysis 2013
Mi rna functional analysis 2013Elsa von Licy
 
Mi rna series i-dec 2012
Mi rna series i-dec 2012Mi rna series i-dec 2012
Mi rna series i-dec 2012Elsa von Licy
 
Mi rna part iii_2013
Mi rna part iii_2013Mi rna part iii_2013
Mi rna part iii_2013Elsa von Licy
 
Wild Type and Mutated BRCA - Differentiation of Breast Cancer - BioGenex
Wild Type and Mutated BRCA - Differentiation of Breast Cancer - BioGenexWild Type and Mutated BRCA - Differentiation of Breast Cancer - BioGenex
Wild Type and Mutated BRCA - Differentiation of Breast Cancer - BioGenexVictoria Miller
 
Meeting the challenges of miRNA research: miRNA and its Role in Human Disease...
Meeting the challenges of miRNA research: miRNA and its Role in Human Disease...Meeting the challenges of miRNA research: miRNA and its Role in Human Disease...
Meeting the challenges of miRNA research: miRNA and its Role in Human Disease...QIAGEN
 
IRJET- Silencing of hnRNP A1 and hnRNP A2/B1 Downregulates the Expression of ...
IRJET- Silencing of hnRNP A1 and hnRNP A2/B1 Downregulates the Expression of ...IRJET- Silencing of hnRNP A1 and hnRNP A2/B1 Downregulates the Expression of ...
IRJET- Silencing of hnRNP A1 and hnRNP A2/B1 Downregulates the Expression of ...IRJET Journal
 
Liu_Jiangyuan_1201662_Presentation
Liu_Jiangyuan_1201662_PresentationLiu_Jiangyuan_1201662_Presentation
Liu_Jiangyuan_1201662_Presentation姜圆 刘
 
Glioma Subtyping and Grading - BioGenex
Glioma Subtyping and Grading - BioGenexGlioma Subtyping and Grading - BioGenex
Glioma Subtyping and Grading - BioGenexVictoria Miller
 
1073957 wp rt2_profilerapp_1012
1073957 wp rt2_profilerapp_10121073957 wp rt2_profilerapp_1012
1073957 wp rt2_profilerapp_1012Elsa von Licy
 
Pcr array whitepaper_app
Pcr array whitepaper_appPcr array whitepaper_app
Pcr array whitepaper_appElsa von Licy
 
Biofluid miRNA profiling: from sample to biomarker: miRNA and its Role in Hum...
Biofluid miRNA profiling: from sample to biomarker: miRNA and its Role in Hum...Biofluid miRNA profiling: from sample to biomarker: miRNA and its Role in Hum...
Biofluid miRNA profiling: from sample to biomarker: miRNA and its Role in Hum...QIAGEN
 
Wp mi script_preamp_0613_lr
Wp mi script_preamp_0613_lrWp mi script_preamp_0613_lr
Wp mi script_preamp_0613_lrElsa von Licy
 

Similar to An gef mi_scriptffpe (20)

An mi script-serum
An mi script-serumAn mi script-serum
An mi script-serum
 
Mi rna toss_set
Mi rna toss_setMi rna toss_set
Mi rna toss_set
 
Mi rna brochure_set
Mi rna brochure_setMi rna brochure_set
Mi rna brochure_set
 
miScript Single Cell Poster
miScript Single Cell PostermiScript Single Cell Poster
miScript Single Cell Poster
 
FFPE Applications Solutions brochure
FFPE Applications Solutions brochureFFPE Applications Solutions brochure
FFPE Applications Solutions brochure
 
Bro gef mi_rna_0212_lr
Bro gef mi_rna_0212_lrBro gef mi_rna_0212_lr
Bro gef mi_rna_0212_lr
 
Mi rna functional analysis 2013
Mi rna functional analysis 2013Mi rna functional analysis 2013
Mi rna functional analysis 2013
 
Mi rna series i-dec 2012
Mi rna series i-dec 2012Mi rna series i-dec 2012
Mi rna series i-dec 2012
 
Mi rna array 2013
Mi rna array 2013Mi rna array 2013
Mi rna array 2013
 
Mi rna part iii_2013
Mi rna part iii_2013Mi rna part iii_2013
Mi rna part iii_2013
 
Wild Type and Mutated BRCA - Differentiation of Breast Cancer - BioGenex
Wild Type and Mutated BRCA - Differentiation of Breast Cancer - BioGenexWild Type and Mutated BRCA - Differentiation of Breast Cancer - BioGenex
Wild Type and Mutated BRCA - Differentiation of Breast Cancer - BioGenex
 
Meeting the challenges of miRNA research: miRNA and its Role in Human Disease...
Meeting the challenges of miRNA research: miRNA and its Role in Human Disease...Meeting the challenges of miRNA research: miRNA and its Role in Human Disease...
Meeting the challenges of miRNA research: miRNA and its Role in Human Disease...
 
IRJET- Silencing of hnRNP A1 and hnRNP A2/B1 Downregulates the Expression of ...
IRJET- Silencing of hnRNP A1 and hnRNP A2/B1 Downregulates the Expression of ...IRJET- Silencing of hnRNP A1 and hnRNP A2/B1 Downregulates the Expression of ...
IRJET- Silencing of hnRNP A1 and hnRNP A2/B1 Downregulates the Expression of ...
 
Liu_Jiangyuan_1201662_Presentation
Liu_Jiangyuan_1201662_PresentationLiu_Jiangyuan_1201662_Presentation
Liu_Jiangyuan_1201662_Presentation
 
Glioma Subtyping and Grading - BioGenex
Glioma Subtyping and Grading - BioGenexGlioma Subtyping and Grading - BioGenex
Glioma Subtyping and Grading - BioGenex
 
1073957 wp rt2_profilerapp_1012
1073957 wp rt2_profilerapp_10121073957 wp rt2_profilerapp_1012
1073957 wp rt2_profilerapp_1012
 
Pcr array whitepaper_app
Pcr array whitepaper_appPcr array whitepaper_app
Pcr array whitepaper_app
 
Biofluid miRNA profiling: from sample to biomarker: miRNA and its Role in Hum...
Biofluid miRNA profiling: from sample to biomarker: miRNA and its Role in Hum...Biofluid miRNA profiling: from sample to biomarker: miRNA and its Role in Hum...
Biofluid miRNA profiling: from sample to biomarker: miRNA and its Role in Hum...
 
Wp mi script_preamp_0613_lr
Wp mi script_preamp_0613_lrWp mi script_preamp_0613_lr
Wp mi script_preamp_0613_lr
 
Mi rna part i_2013
Mi rna part i_2013Mi rna part i_2013
Mi rna part i_2013
 

More from Elsa von Licy

Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...
Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...
Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...Elsa von Licy
 
Strategie Decisions Incertitude Actes conference fnege xerfi
Strategie Decisions Incertitude Actes conference fnege xerfiStrategie Decisions Incertitude Actes conference fnege xerfi
Strategie Decisions Incertitude Actes conference fnege xerfiElsa von Licy
 
Neuropsychophysiologie
NeuropsychophysiologieNeuropsychophysiologie
NeuropsychophysiologieElsa von Licy
 
L agressivite en psychanalyse (21 pages 184 ko)
L agressivite en psychanalyse (21 pages   184 ko)L agressivite en psychanalyse (21 pages   184 ko)
L agressivite en psychanalyse (21 pages 184 ko)Elsa von Licy
 
C1 clef pour_la_neuro
C1 clef pour_la_neuroC1 clef pour_la_neuro
C1 clef pour_la_neuroElsa von Licy
 
Vuillez jean philippe_p01
Vuillez jean philippe_p01Vuillez jean philippe_p01
Vuillez jean philippe_p01Elsa von Licy
 
Spr ue3.1 poly cours et exercices
Spr ue3.1   poly cours et exercicesSpr ue3.1   poly cours et exercices
Spr ue3.1 poly cours et exercicesElsa von Licy
 
Plan de cours all l1 l2l3m1m2 p
Plan de cours all l1 l2l3m1m2 pPlan de cours all l1 l2l3m1m2 p
Plan de cours all l1 l2l3m1m2 pElsa von Licy
 
Bioph pharm 1an-viscosit-des_liquides_et_des_solutions
Bioph pharm 1an-viscosit-des_liquides_et_des_solutionsBioph pharm 1an-viscosit-des_liquides_et_des_solutions
Bioph pharm 1an-viscosit-des_liquides_et_des_solutionsElsa von Licy
 
Poly histologie-et-embryologie-medicales
Poly histologie-et-embryologie-medicalesPoly histologie-et-embryologie-medicales
Poly histologie-et-embryologie-medicalesElsa von Licy
 
Methodes travail etudiants
Methodes travail etudiantsMethodes travail etudiants
Methodes travail etudiantsElsa von Licy
 
Atelier.etude.efficace
Atelier.etude.efficaceAtelier.etude.efficace
Atelier.etude.efficaceElsa von Licy
 
There is no_such_thing_as_a_social_science_intro
There is no_such_thing_as_a_social_science_introThere is no_such_thing_as_a_social_science_intro
There is no_such_thing_as_a_social_science_introElsa von Licy
 

More from Elsa von Licy (20)

Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...
Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...
Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...
 
Strategie Decisions Incertitude Actes conference fnege xerfi
Strategie Decisions Incertitude Actes conference fnege xerfiStrategie Decisions Incertitude Actes conference fnege xerfi
Strategie Decisions Incertitude Actes conference fnege xerfi
 
Rainville pierre
Rainville pierreRainville pierre
Rainville pierre
 
Neuropsychophysiologie
NeuropsychophysiologieNeuropsychophysiologie
Neuropsychophysiologie
 
L agressivite en psychanalyse (21 pages 184 ko)
L agressivite en psychanalyse (21 pages   184 ko)L agressivite en psychanalyse (21 pages   184 ko)
L agressivite en psychanalyse (21 pages 184 ko)
 
C1 clef pour_la_neuro
C1 clef pour_la_neuroC1 clef pour_la_neuro
C1 clef pour_la_neuro
 
Hemostase polycop
Hemostase polycopHemostase polycop
Hemostase polycop
 
Antiphilos
AntiphilosAntiphilos
Antiphilos
 
Vuillez jean philippe_p01
Vuillez jean philippe_p01Vuillez jean philippe_p01
Vuillez jean philippe_p01
 
Spr ue3.1 poly cours et exercices
Spr ue3.1   poly cours et exercicesSpr ue3.1   poly cours et exercices
Spr ue3.1 poly cours et exercices
 
Plan de cours all l1 l2l3m1m2 p
Plan de cours all l1 l2l3m1m2 pPlan de cours all l1 l2l3m1m2 p
Plan de cours all l1 l2l3m1m2 p
 
M2 bmc2007 cours01
M2 bmc2007 cours01M2 bmc2007 cours01
M2 bmc2007 cours01
 
Feuilletage
FeuilletageFeuilletage
Feuilletage
 
Chapitre 1
Chapitre 1Chapitre 1
Chapitre 1
 
Biophy
BiophyBiophy
Biophy
 
Bioph pharm 1an-viscosit-des_liquides_et_des_solutions
Bioph pharm 1an-viscosit-des_liquides_et_des_solutionsBioph pharm 1an-viscosit-des_liquides_et_des_solutions
Bioph pharm 1an-viscosit-des_liquides_et_des_solutions
 
Poly histologie-et-embryologie-medicales
Poly histologie-et-embryologie-medicalesPoly histologie-et-embryologie-medicales
Poly histologie-et-embryologie-medicales
 
Methodes travail etudiants
Methodes travail etudiantsMethodes travail etudiants
Methodes travail etudiants
 
Atelier.etude.efficace
Atelier.etude.efficaceAtelier.etude.efficace
Atelier.etude.efficace
 
There is no_such_thing_as_a_social_science_intro
There is no_such_thing_as_a_social_science_introThere is no_such_thing_as_a_social_science_intro
There is no_such_thing_as_a_social_science_intro
 

An gef mi_scriptffpe

  • 1. ApplicationNote Unlock miRNA expression profiles from FFPE samples using miScript® miRNA PCR Arrays Krishna Amin and Jonathan M. Shaffer, Ph.D. 1.E+04 miRNA expression profiling provides a valuable window into changes occurring in a biological system. Due to their stability and size, miRNAs can be readily extracted from FFPE samples using the miRNeasy FFPE Kit. Here, we use the miScript PCR System to profile miRNA expression changes in total RNA samples isolated from FFPE normal and tumor lung tissues. Profile miRNA expression data in FFPE tissue from tissues. miScript miRNA PCR Arrays have been organized into biological and disease-focused panels using state-of-the-art bioinformatics 1.E+04 reverse crosslinking and efficiently release total RNA containing miRNA 1.E-04 1.E+03 transcription reactions. The miRNeasy FFPE Kit is specifically optimized to 1.E-03 1.E+02 can be heavily fragmented, and formalin crosslinking can impair reverse 1.E-02 1.E+01 material for cDNA synthesis (Table 1). RNA isolated from FFPE samples 1.E-01 1.E+00 miRNA PCR Arrays, and uses total RNA that contains miRNA as the starting 1.E+00 1.E-01 RT Kit, miScript SYBR® Green PCR Kit, miScript Primer Assays, and miScript 1.E+01 1.E-02 archived FFPE samples. The miScript PCR System consists of the miScript II 1.E+02 1.E-03 provides a sample-to-result solution for miRNA expression profiling using 1.E+03 1.E-04 The miScript PCR System, in conjunction with the miRNeasy FFPE Kit, 2-∆CT : Tumor lung FFPE tissue QIAGEN Inc., Frederick, MD, USA 2-∆CT : Normal lung FFPE tissue Figure 1. miRNA expression changes identified in tumor lung tissue. A scatter plot of 2-∆CT values shows significant differences in mature miRNA expression levels between normal and tumor lung tissue. These include miRNAs whose expression levels have been previously shown to be up-regulated (hsa-miR-9, hsa-miR-18a, hsa-miR-210) and down-regulated (hsa-miR-126, hsa-miR-143) in lung cancer (1-4). For this experiment, 5 µm FFPE lung tissue sections were purchased from Asterand, and total RNA was prepared using the miRNeasy FFPE Kit. 125 ng RNA was reverse transcribed using the miScript II RT Kit with miScript HiSpec Buffer, and 0.5 ng cDNA was added to each well of the Human miFinder miScript miRNA PCR Array. algorithms and text mining tools. These panels profile the most relevant Pathways for miScript miRNA PCR Arrays miRNA expression changes in total RNA from FFPE samples (Figure 1), with „„ Complete miRNome highly reproducible, reliable results (Figure 2). Table 1. FFPE tissue recommendations Step Starting materials/conditions Formalin fixation/paraffin embedding Use tissue less than 5 mm thick. Fix in 4–10% neutral-buffered formalin with a maximum fixation time of 24 hours. Total RNA preparation from FFPE tissues Use sections 5–20 mm thick, or multiple sections with combined thickness no greater than 40 mm and surface area <250 mm2. RNA input for cDNA conversion Use 125 to 250 ng per sample for pathway-focused arrays and 250 to 500 ng for whole miRNome. Amount of FFPE tissue required depends on amount of tissue embedded and RNA quality. RNA quality will vary due to fixation and storage conditions. „„ miFinder „„ Inflammatory Response & Autoimmunity „„ Ovarian Cancer „„ Neurological Development & Disease „„ Cell Differentiation & Development „„ Serum & Plasma „„ Brain Cancer „„ Breast Cancer „„ Cancer PathwayFinder „„ Immunopathology Sample & Assay Technologies
  • 2. 40 40 Normal A 32 28 28 CT value 36 32 CT value 36 Tumor B 24 20 16 24 20 16 FFPE isolation 1 FFPE isolation 2 FFPE isolation 3 12 8 FFPE isolation 1 FFPE isolation 2 FFPE isolation 3 12 8 4 4 1 7 13 19 25 31 37 43 49 55 61 67 73 1 Human miFinder miRNA Assay 7 13 19 25 31 37 43 49 55 61 67 73 Human miFinder miRNA Assay Figure 2. miScript FFPE Kit and miFinder miScript miRNA PCR Array provide highly reproducible results, isolation to isolation. The raw data presented for one normal A and one tumor B FFPE lung tissue donor source demonstrates the high reproducibility that can be achieved using the miRNeasy FFPE Kit in combination with the miScript PCR System and miScript miRNA PCR Arrays. Each isolation was from a different section from the same donor, with the normal and tumor tissues coming from different donors. Ordering Information Product Contents Cat. no. miRNome miScript miRNA PCR Array miRNome panels of miRNA assays Varies miScript miRNA PCR Array Pathway- or disease-focused panels of miRNA assays Varies Custom miScript miRNA PCR Array Custom panels of miRNA assays Varies miRNeasy FFPE Kit (50) Columns, plasticware, and reagents for 50 preps 217504 miScript SYBR® Green PCR Kit (200) Reagents for 200 x 50 µl PCRs 218073 miScript Primer Assay (100) miRNA-specific primer for 100 x 50 µl PCRs Varies* miScript II RT Kit (12) Reagents for 12 x 20 µl cDNA synthesis reactions 218160 * Visit GeneGlobe to browse and order these products (www.qiagen.com/GeneGlobe). Discover more, visit www.qiagen.com/miRNA ! For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services or your local distributor. References 1. Liu, C.G., et al. (2004) An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc. Natl. Acad. Sci. USA 101, 9740. 2. Crawford, M., et al. (2009) MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem. Biophys. Res. Commun. 388, 483. 3. Hayashita, Y., et al. (2005) A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 65, 9628. 4. Yanaihara, N., et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9, 189. Trademarks: QIAGEN®, miScript® (QIAGEN Group); SYBR® (Life Technologies Corporation). 1070749 12/2011 © 2011, QIAGEN, all rights reserved. www.qiagen.com Australia n 1-800-243-066 Austria n 00800-22448000 Belgium n 00800-22448000 Brazil n 0800-557779 Canada n 0800-362-7737 China n 0800-988-0325 Denmark n 00800-22448000 Finland n 00800-22448000 France n 00800-22448000 Germany n 00800-22448000 Ireland n 00800-22448000 Italy n 00800-22448000 Japan n 03-5632-9610 Luxembourg n 00800-22448000 Mexico n 01-800-7742-436 Netherlands n 00800-22448000 Norway n 00800-22448000 Singapore n 1800-742-4368 Sweden n 00800-22448000 Switzerland n 00800-22448000 UK n 00800-22448000 USA n 1-888-503-3187 Sample & Assay Technologies